US pharma major Merck (NYSE: MRK) is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed ...
GlobalData on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
13d
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Goldman Sachs analyst Chris Shibutani has reiterated their bullish stance on MRK stock, giving a Buy rating today. Chris Shibutani has given his Buy rating due to a combination of factors surrounding ...
In a split showing for cancer powerhouse Merck, its immunotherapy Keytruda continued a losing streak in prostate cancer but chalked up a win to pressure an industry-first approval by AstraZeneca.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback